Physician profile
Brian Jones
NPI 1629575113
$2,276.94
in general payments reported to CMS, 2019-2025
32 companies · $288 in 2025
The $288 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.66 · 2022: $523 · 2023: $657 · 2024: $795 · 2025: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,740.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,740.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $362.57 | 2021-2025 | |
| Novo Nordisk INC | $248.99 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $243.35 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $238.18 | 2022-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Pfizer INC. | $192.45 | 2023-2024 | |
| Amgen INC. | $86.41 | 2023-2025 | Repatha, Otezla, Prolia |
| Takeda Pharmaceuticals U.S.A., INC. | $75.66 | 2023-2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.09 | 2022-2025 | Xifaxan |
| Ironshore Pharmaceuticals INC. | $64.09 | 2022-2024 | Jornay Pm |
| Bayer Healthcare Pharmaceuticals INC. | $56.49 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $54.65 | 2022-2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.40 | 2023 | Tradjenta |
| Axsome Therapeutics, INC. | $53.11 | 2024 | Auvelity |
| Biohaven Pharmaceutical Holding Company Ltd. | $43.49 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $42.93 | 2024-2025 | Caplyta |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $39.80 | 2022 | |
| Astellas Pharma US INC | $39.40 | 2024 | Veozah |
| Vanda Pharmaceuticals INC. | $31.79 | 2025 | Fanapt |
| Supernus Pharmaceuticals, INC. | $31.56 | 2022-2023 | Qelbree |
| Sanofi-Aventis U.S. LLC | $29.61 | 2022-2024 | |
| Edwards Lifesciences Corporation | $28.30 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Merck Sharp & Dohme LLC | $25.30 | 2022-2024 | Gardasil, Vaxelis, Capvaxive |
| Corium, LLC | $20.41 | 2023 | Azstarys |
| Abbott Laboratories | $19.85 | 2022 | |
| Antares Pharma, INC. | $19.69 | 2023 | Xyosted, Tlando, Nocdurna |
| Radius Health, INC. | $18.95 | 2024 | Tymlos |
| Sanofi Pasteur INC. | $17.76 | 2022 | |
| Lundbeck LLC | $16.34 | 2024 | Vyepti |
| Organon LLC | $14.98 | 2023 | |
| Ibsa Pharma INC. | $14.09 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.63 | 2023 | Quviviq |
| Exact Sciences Corporation | $13.62 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.